HK69595A - Steroidal 17alpha-silyl ethers and process to corticoids and progesterones - Google Patents

Steroidal 17alpha-silyl ethers and process to corticoids and progesterones

Info

Publication number
HK69595A
HK69595A HK69595A HK69595A HK69595A HK 69595 A HK69595 A HK 69595A HK 69595 A HK69595 A HK 69595A HK 69595 A HK69595 A HK 69595A HK 69595 A HK69595 A HK 69595A
Authority
HK
Hong Kong
Prior art keywords
corticoids
progesterones
17alpha
steroidal
silyl ethers
Prior art date
Application number
HK69595A
Other languages
English (en)
Inventor
Douglas Alan Livingston
Bruce Allen Pearlman
Scott Denmark
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HK69595A publication Critical patent/HK69595A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK69595A 1986-11-05 1995-05-04 Steroidal 17alpha-silyl ethers and process to corticoids and progesterones HK69595A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92763386A 1986-11-05 1986-11-05
US2045787A 1987-03-02 1987-03-02

Publications (1)

Publication Number Publication Date
HK69595A true HK69595A (en) 1995-05-12

Family

ID=26693463

Family Applications (1)

Application Number Title Priority Date Filing Date
HK69595A HK69595A (en) 1986-11-05 1995-05-04 Steroidal 17alpha-silyl ethers and process to corticoids and progesterones

Country Status (15)

Country Link
US (1) US4977255A (es)
EP (2) EP0334875A1 (es)
JP (2) JP2549721B2 (es)
KR (1) KR960006394B1 (es)
AT (1) ATE75484T1 (es)
AU (1) AU8335587A (es)
CA (1) CA1317283C (es)
DE (1) DE3778651D1 (es)
ES (1) ES2039249T3 (es)
GR (1) GR3005079T3 (es)
HK (1) HK69595A (es)
HU (2) HU209783B (es)
PT (1) PT86083B (es)
SG (1) SG33647G (es)
WO (1) WO1988003534A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
ATE190623T1 (de) * 1990-06-11 2000-04-15 Alcon Lab Inc Verwendung von steroiden zur inhibierung von angiogenesis
AU684946B2 (en) * 1994-05-09 1998-01-08 Pharmacia & Upjohn Company SYNTHESIS OF 17B CYANO-3-ETHOXY-17a-HYDROXY-6-METHYLANDROSTA-3,5,9-(11)-TRIEN 9(11)-triene
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
EP1265911B1 (en) 2000-03-17 2008-05-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
KR100694079B1 (ko) 2005-01-08 2007-03-12 학교법인 대양학원 유무선 통합 네트워크에서 ｐ２ｐ 서비스를 위한 데이터다운로드 방법 및 그 노드
ES2744879T3 (es) 2008-05-28 2020-02-26 Reveragen Biopharma Inc Moduladores esteroideos no hormonales de NF-kappaB para el tratamiento de enfermedades
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
CN103601786A (zh) * 2013-11-22 2014-02-26 湖南新合新生物医药有限公司 甲基泼尼松龙关键中间体的制备方法
CN103833814A (zh) * 2014-03-06 2014-06-04 浙江仙居君业药业有限公司 17羟基-孕甾-4-烯-3,20-二酮-21-醋酸酯的制备方法
CN103910775A (zh) * 2014-03-31 2014-07-09 仙居县圃瑞药业有限公司 17α-羟基黄体酮的合成方法
CN104311619A (zh) * 2014-07-08 2015-01-28 仙居县圃瑞药业有限公司 一种采用串联法合成黄体酮的方法
CN104311625B (zh) * 2014-11-06 2016-03-23 江西赣亮医药原料有限公司 一种醋酸氟轻松中间体的制备方法
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
CN105801651B (zh) * 2016-04-19 2018-03-06 浙江仙居君业药业有限公司 一种17α‑羟基黄体酮的合成方法
CN109517020B (zh) * 2018-11-22 2020-12-15 湖南原野医药有限公司 Delta-9,11-羟基黄体酮的合成方法
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
CN117257775A (zh) * 2023-11-01 2023-12-22 南京羚诺生物医药技术研究院有限公司 一种子宫内膜异位症用口溶膜制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2082129A5 (es) * 1970-03-04 1971-12-10 Roussel Uclaf
SE387854B (sv) * 1973-11-21 1976-09-20 O L Lindblad Paverkningsorgan, foretredesvis avsett att anvendas i samband med fordonsekerhetsselar
US4081537A (en) * 1975-10-10 1978-03-28 Schering Aktiengesellschaft Δ15 -Steroids and pharmaceutical compositions thereof
JPS5762298A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-cyanosteroid
JPS5762296A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-hydroxyprogesterone derivative
JPS5762299A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-cyanosteroid
DE3585547D1 (de) * 1984-02-03 1992-04-16 Upjohn Co Steroide mit einer enamid- oder enimidgruppe sowie ihre herstellung.
US4585590A (en) * 1984-02-03 1986-04-29 The Upjohn Company Cyanohydrin process
US4548748A (en) * 1984-02-03 1985-10-22 The Upjohn Company Cyanohydrin process
US4500461A (en) * 1984-02-03 1985-02-19 The Upjohn Company Cyanohydrin process
DE3427486A1 (de) * 1984-07-23 1986-01-30 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von 6(alpha)-methylsteroiden

Also Published As

Publication number Publication date
HUT65138A (en) 1994-04-28
PT86083B (pt) 1990-11-20
CA1317283C (en) 1993-05-04
SG33647G (en) 1995-09-01
HU209783B (en) 1994-10-28
US4977255A (en) 1990-12-11
ATE75484T1 (de) 1992-05-15
GR3005079T3 (es) 1993-05-24
HU892262D0 (en) 1992-09-28
ES2039249T3 (es) 1993-09-16
EP0268400A1 (en) 1988-05-25
DE3778651D1 (de) 1992-06-04
KR960006394B1 (ko) 1996-05-15
EP0334875A1 (en) 1989-10-04
JPH07278183A (ja) 1995-10-24
JPH02500911A (ja) 1990-03-29
JP2549721B2 (ja) 1996-10-30
JP2515967B2 (ja) 1996-07-10
EP0268400B1 (en) 1992-04-29
AU8335587A (en) 1988-06-01
PT86083A (en) 1987-12-01
KR890700130A (ko) 1989-03-10
WO1988003534A1 (en) 1988-05-19

Similar Documents

Publication Publication Date Title
PT86083A (en) Steroidal 17 alpha-silyl ethers and process to corticoids and progesterones
GB2157885B (en) Process for producing cmos structures with bipolar transistors
AU515357B2 (en) Froth flotation process and collector composition
AU528287B2 (en) Improvements relating to the treatment of flat glass
AU2047276A (en) 9 21-dihalogeno-11 17 -dihydroxy-6 -fluro-16-methyl-pregna-1,4-diene-3,20-diones
HUT45399A (en) Production of seditive compositions by applying medetomidine
GB2019848B (en) 3-(acyloxy or alkoxy) - 9,11 - epoxypregna - 1,3,5(6) - trienes, and their use in the synthesis of 6 -halo corticoids
GB2018258A (en) 3 acetoxy & 11 epoxy pregna 3,5 dienes and 1,3,5 trienes and their use in the synthesis of 6 halocorticoids
DE2962925D1 (en) Process for the preparation of pure potassium ribonate and pure ribonolactone
AU591305B2 (en) Improved process for preparing 5,6-substitued-2,4- quinazolinediamines and novel intermediates
ES8405812A1 (es) Un procedimiento de preparacion de nuevos derivados diclorados de la serie 16- -metil-pregnano
AU596688B2 (en) Process for the production of low carbon silicon
ES486851A1 (es) Un procedimiento de preparacion de acido 3a,7b-dihidroxico- lanico
DE2960478D1 (en) Coke for use in the production of gray iron; method of producing said coke and method of producing gray iron by using said coke
BG33735A3 (bg) Метод за получаване на заместени в 17-та позиция стероиди от прегнановия ред
DE2963006D1 (en) Microorganisms and their use in producing androst-4-ene-3,17-dione
DE2861758D1 (en) Process for the manufacture of 3,4-dihydro-benzopyran derivatives and starting materials in this process
DE2966657D1 (en) Process for dehydroxylation of 13-hydroxygibberellins and intermediates useful in the process
ZA793619B (en) Process for dehydroxylation of 13-hydroxygibberellins and intermediates useful in the process
AP9600790A0 (en) Process for preparation of substituted steroidal dienes and novel intermediates used in said process.
AU4104778A (en) Process for beneficiation of titanium ores
EP0104054A3 (en) 16-methylene-steroids and their preparation
KR790000589B1 (en) Method for producing 6l-fluoro-17,21-dehydroxy-16b-methylpregna-4,9(11)diene-3,20-dione17,21-diacetate
AU2910589A (en) Diagnostic method for primary biliary cirrhosis and antibodies suitable to be used in the method
ZA792376B (en) Process for the stereospecific production of imidazolyl-oximes and use of the imidazolyl-oxime stereoisomers in the stereospecific production of imadazolyl-oxime ethers

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20061102